

Supplement IDS submitted herewith. U.S. Patent No. 5,688,651 was cited in the Supplemental IDS submitted August 25, 2000. At the request of the Examiner, U.S. Patent No. 5,688,651 was cited a second time in the Supplemental IDS filed on August 20, 2001.

Support for the amendment to claim 1 is found throughout the specification as filed. No new matter has been added with this amendment. Claim 1 has been amended to recite a disease characterized by amyloid deposit "comprising A β peptide." Support for the amendment may be found, *e.g.*, in the specification on page 1, lines 26-27 and page 41, line 31 to page 42, line 5. Claim 1 has been amended to recite an antibody that specifically binds to the "A β peptide." Support for the amendment may be found, *e.g.*, in the specification on page 2, lines 25-28; page 3, lines 1-4; page 14, line 14 to page 15, line 2; page 57, lines 25-31; page 58, Table 6; and, in claims 1, 9, 25-28, and 57-58 as originally filed. Claim 1 has been amended to recite in a regime effective to prevent or treat the disease "wherein the administering of the antibody reduces levels of A β in the brain of the patient." Support for the amendment may be found, *e.g.*, at page 72, line 17 to page 78, line 10 of Example XI.

Claims depending from canceled claim 9, namely, claims 10-15, 20-24, 29, and 31, have been amended to depend from claim 2.

Support for new claims 68-81 is found throughout the specification. Support for new claims 68 and 75 is found, *e.g.*, at page 78, lines 12-26. Support for new claims 69 and 74 is found, *e.g.*, at page 3, lines 5-6; page 28, lines 11-13; and, in claim 22 as originally filed. Support for new claims 70, 71, 76, and 77 is found, *e.g.*, at page 28, lines 17-21. Support for new claims 72 and 78 is found, *e.g.*, at page 28, lines 19-20. Support for new claims 73 and 79 is found, *e.g.*, at page 35, lines 31-33. Support for new claims 80 and 81 is found, *e.g.*, at page 2, lines 30-33; page 3, lines 2-3; page 14, lines 29-30; page 28, lines 22-24; and in claims 10 and 11 as originally filed. In view of the foregoing support, Applicant believes no new matter has been introduced and respectfully request the new claims 68-81 be entered.

Applicant believes that no fee is required for submission of this second Amendment. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Rosemarie L. Celli". The signature is fluid and cursive, with a large initial "R" and a stylized "C".

Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400
Fax: (650) 326-2422
RLC:lah
PA 3236775 v1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Twice amended) A method of preventing or treating a disease characterized by amyloid deposit comprising A β peptide in a patient, comprising administering to the patient an antibody that specifically binds to A β peptide[the amyloid deposit or a component thereof], in a regime effective to prevent or treat the disease, wherein the administering of the antibody reduces levels of A β in the brain of the patient.
10. The method of claim 2[9], wherein the antibody is a human antibody.
11. The method of claim 2[9], wherein the antibody is a humanized antibody.
12. The method of claim 2[9], wherein the antibody is a chimeric antibody.
13. The method of claim 2[9], wherein the antibody is a mouse antibody.
14. The method of claim 2[9], wherein the antibody is a polyclonal antibody.
15. The method of claim 2[9], wherein the antibody is a monoclonal antibody.
20. The method of claim 2[9], wherein the antibody is a Fab fragment.
21. The method of claim 2[9], wherein a chain of the antibody is fused to a heterologous polypeptide.
22. The method of claim 2[9], wherein the dosage of antibody is at least 1 mg/kg body weight of the patient.
23. The method of claim 2[9], wherein the dosage of antibody is at least 10 mg/kg body weight of the patient.
24. The method of claim 2[9], wherein the antibody is administered with a carrier as a pharmaceutical composition.

29. The method of claim 2[9], wherein the antibody is a human antibody to A β prepared from B cells from a human immunized with an A β peptide.

31. The method of claim 2[9], wherein the antibody specifically binds to A β peptide without binding to full-length amyloid precursor protein (APP).